monarchE demonstrates positive results in Phase 3 study of 5,637 people whose early breast cancer is at a high risk of recurrence
Verzenio given with standard endocrine therapy showed improvement compared to standard endocrine therapy alone
Verzenio is the only CDK4 & 6 inhibitor to demonstrate statistically significant improvement in invasive disease-free survival in this setting
Lilly will submit data from monarchE to regulatory authorities around the world
PR Newswire
INDIANAPOLIS, June 16, 2020